Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[89Zr]trastuzumab PET/CT for predicting pathologic complete response in HER2-positive breast cancer
2018-004247-23Phase 2Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 89Zr-trastuzumab in breast cancer, sponsored by Leiden University Medical Center. Started Dec 2018; status: terminated.
02
Drugs
89Zr-trastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-004247-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004247-23.